Show simple item record

dc.contributor.authorHenson, Caroline C
dc.contributor.authorAnandadas, Carmel N
dc.contributor.authorBarraclough, Lisa H
dc.contributor.authorSwindell, Ric
dc.contributor.authorWest, Catharine M L
dc.contributor.authorDavidson, Susan E
dc.date.accessioned2013-08-05T13:46:17Z
dc.date.available2013-08-05T13:46:17Z
dc.date.issued2013-07-01
dc.identifier.citationThe case for including bowel urgency in toxicity reporting after pelvic cancer treatment. 2013, 11 (7):827-33 J Natl Compr Canc Netwen_GB
dc.identifier.issn1540-1413
dc.identifier.pmid23847219
dc.identifier.urihttp://hdl.handle.net/10541/297421
dc.description.abstractBowel toxicity is a major complication of cancer treatment, and its accurate reporting is important for assessing outcomes. The NCI's Common Terminology Criteria for Adverse Events (CTCAE) is the preferred method for capturing adverse events after all cancer treatments, particularly within clinical trials. However, the CTCAE version 4 does not include urgency of defecation as an item, despite this being one of the most common and persistent adverse consequences of treatment of pelvic cancers. The importance of bowel urgency to patients is well documented, and this treatment effect has a negative impact on social function and quality of life. Bowel urgency is also important clinically because it may represent significant underlying problems. This article presents the case for including patient reported assessment of bowel urgency as an independent item in cancer treatment adverse event reporting.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of the National Comprehensive Cancer Network : JNCCNen_GB
dc.titleThe case for including bowel urgency in toxicity reporting after pelvic cancer treatment.en
dc.typeArticleen
dc.contributor.departmentFrom the Departments of Radiotherapy Related Research, Clinical Oncology, and Statistics, The Christie NHS Foundation Trust, Manchester, United Kingdom.en_GB
dc.identifier.journalJournal of the National Comprehensive Cancer Networken_GB
html.description.abstractBowel toxicity is a major complication of cancer treatment, and its accurate reporting is important for assessing outcomes. The NCI's Common Terminology Criteria for Adverse Events (CTCAE) is the preferred method for capturing adverse events after all cancer treatments, particularly within clinical trials. However, the CTCAE version 4 does not include urgency of defecation as an item, despite this being one of the most common and persistent adverse consequences of treatment of pelvic cancers. The importance of bowel urgency to patients is well documented, and this treatment effect has a negative impact on social function and quality of life. Bowel urgency is also important clinically because it may represent significant underlying problems. This article presents the case for including patient reported assessment of bowel urgency as an independent item in cancer treatment adverse event reporting.


This item appears in the following Collection(s)

Show simple item record